enGene Holdings Inc. Warrants
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. enGen… Read more
enGene Holdings Inc. Warrants (ENGNW) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of October 2025: -0.149x
Based on the latest financial reports, enGene Holdings Inc. Warrants (ENGNW) has a cash flow conversion efficiency ratio of -0.149x as of October 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-24.96 Million) by net assets ($167.71 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
enGene Holdings Inc. Warrants - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how enGene Holdings Inc. Warrants's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
enGene Holdings Inc. Warrants Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of enGene Holdings Inc. Warrants ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Suwen Tekstil Sanayi Pazarlama AS
IS:SUWEN
|
0.354x |
|
Eltel AB
ST:ELTEL
|
0.251x |
|
Lux Industries Limited
NSE:LUXIND
|
-0.130x |
|
CleanSpark, Inc. Warrant
NASDAQ:CLSKW
|
-0.117x |
|
Mogan Enerji Yatırım Holding As
IS:MOGAN
|
0.068x |
|
Abion Inc.
KQ:203400
|
-0.336x |
|
Hope Education Group Co. Ltd
F:HE1
|
0.052x |
|
Sri Rejeki Isman(Sritex)PT
JK:SRIL
|
0.007x |
Annual Cash Flow Conversion Efficiency for enGene Holdings Inc. Warrants (2021–2025)
The table below shows the annual cash flow conversion efficiency of enGene Holdings Inc. Warrants from 2021 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-10-31 | $167.71 Million | $-99.24 Million | -0.592x | -234.11% |
| 2024-10-31 | $272.61 Million | $-48.28 Million | -0.177x | +48.12% |
| 2023-10-31 | $72.49 Million | $-24.74 Million | -0.341x | -147.25% |
| 2022-10-31 | $127.42 Million | $-17.59 Million | -0.138x | -10.03% |
| 2021-10-31 | $127.39 Million | $-15.98 Million | -0.125x | -- |